Hepatocyte growth factor: molecular biomarker and player in cardioprotection and cardiovascular regeneration
- PMID: 22318499
- DOI: 10.1160/TH11-10-0711
Hepatocyte growth factor: molecular biomarker and player in cardioprotection and cardiovascular regeneration
Abstract
The liver possesses impressive regenerative capacities. Grafts of embryonic liver explants and liver explant-conditioned media have been shown to enhance the mitotic activity of hepatocytes. Hepatocyte growth factor (HGF), also named scatter factor (SF), has been identified as a primary candidate in promoting and regulating liver regeneration. Although initially thought to be a liver-specific mitogen, HGF was later reported to have mitogenic, motogenic, morphogenic, and anti-apoptotic activities in various cell types. By promoting angiogenesis and inhibiting apoptosis, endogenous HGF may play an important role in cardioprotection as well as in the regeneration of endothelial cells and cardiomyocytes after myocardial infarction. Since serum concentration of HGF increases in the early phase of myocardial infarction and in heart failure, HGF may also play a key role as a prognostic and diagnostic biomarker of cardiovascular disease. Here we discuss the role of HGF as a biomarker and mediator in cardioprotection and cardiovascular regeneration.
Similar articles
-
Hepatocyte growth factor induces angiogenesis in injured lungs through mobilizing endothelial progenitor cells.Biochem Biophys Res Commun. 2004 Nov 5;324(1):276-80. doi: 10.1016/j.bbrc.2004.09.049. Biochem Biophys Res Commun. 2004. PMID: 15465014
-
Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets.Gene Ther. 2000 Mar;7(5):417-27. doi: 10.1038/sj.gt.3301104. Gene Ther. 2000. PMID: 10694824
-
Hepatocyte growth factor as cardiovascular hormone: role of HGF in the pathogenesis of cardiovascular disease.Endocr J. 2002 Jun;49(3):273-84. doi: 10.1507/endocrj.49.273. Endocr J. 2002. PMID: 12201209 Review.
-
Cellular and molecular mechanisms of HGF/Met in the cardiovascular system.Clin Sci (Lond). 2015 Dec;129(12):1173-93. doi: 10.1042/CS20150502. Clin Sci (Lond). 2015. PMID: 26561593 Review.
-
Induction of angiogenesis and inhibition of apoptosis by hepatocyte growth factor effectively treats postischemic heart failure.J Card Surg. 2005 Jan-Feb;20(1):93-101. doi: 10.1111/j.0886-0440.2005.200373.x. J Card Surg. 2005. PMID: 15673421
Cited by
-
Immunogenicity Risk Assessment for PEGylated Therapeutics.AAPS J. 2020 Jan 28;22(2):35. doi: 10.1208/s12248-020-0420-0. AAPS J. 2020. PMID: 31993858 Review.
-
Targeted plasma proteomics reveals signatures discriminating COVID-19 from sepsis with pneumonia.Respir Res. 2023 Feb 24;24(1):62. doi: 10.1186/s12931-023-02364-y. Respir Res. 2023. PMID: 36829233 Free PMC article.
-
Treatment of Myocardial Infarction with Gene-modified Mesenchymal Stem Cells in a Small Molecular Hydrogel.Sci Rep. 2017 Nov 20;7(1):15826. doi: 10.1038/s41598-017-15870-z. Sci Rep. 2017. PMID: 29158523 Free PMC article.
-
Identification of Inflammatory and Disease-Associated Plasma Proteins that Associate with Intake of Added Sugar and Sugar-Sweetened Beverages and Their Role in Type 2 Diabetes Risk.Nutrients. 2020 Oct 14;12(10):3129. doi: 10.3390/nu12103129. Nutrients. 2020. PMID: 33066363 Free PMC article.
-
Hepatocyte Growth Factor Receptor c-Met Instructs T Cell Cardiotropism and Promotes T Cell Migration to the Heart via Autocrine Chemokine Release.Immunity. 2015 Jun 16;42(6):1087-99. doi: 10.1016/j.immuni.2015.05.014. Epub 2015 Jun 9. Immunity. 2015. PMID: 26070483 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
